

Corporate Office: Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bengaluru — 560076, India T: +91 80 6784 0738 Registered Office: Cyber One, Unit No. 902, Sector 30A Plot No - 4 & 6, Vashi, Navi Mumbai 400703 India F: +91 22 2789 2924 T: 91 22 2789 2942

Date: August 04, 2025

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street Mumbai- 400001

Scrip Code: 544292 ISIN: INE013P01021 National Stock Exchange of India Ltd

Exchange Plaza, C-1, Block G, Bandra Kurla Complex,

Bandra (E) Mumbai – 400 051

Symbol: ONESOURCE

Dear Sir/ Madam,

Sub: Update:

In-principle approval of the Board of Directors to evaluate acquisition of Sterile Injectable CDMO and CMO businesses of Steriscience Pte. Limited ("SteriScience SG") and Brooks Steriscience Limited.

The Board of Directors at their meeting held today i.e., August 04, 2025 has given their in-principle approval to evaluate potential acquisition of the Sterile Injectable CDMO and CMO businesses of Steriscience and Carbapenem facility of Brooks Steriscience Limited.

The potential transaction, if finalised and consummated, will bring in the following facilities into OneSource:

- USFDA-approved sterile fill-finish manufacturing facility in Warsaw, Poland, with the ability to expand
 capacity for drug-device combination products for our global partners. This site serves marquee global players
 and several IP-led products.
- An integrated, state-of-the-art, USFDA-approved carbapenem facility in Vadodara, India operated under the name of Brooks Steriscience Limited.

Steriscience SG and Brooks Steriscience Limited are majorly owned directly/ indirectly by the Promoters of the Company.

Board has authorised the Management to undertake detailed evaluation of the potential transaction including suggesting optimal structure and present to the Audit Committee, Committee of Independent Directors and the Board of Directors.

Further, Board also authorised the Management to appoint Consultants, Advisors (Legal and Financial), Valuers, Merchant Bankers and such other intermediaries/ agencies as may be required to evaluate the potential transaction.

Company will make appropriate disclosures in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, post consideration and approval of the matter by the Board.

You are requested to kindly take the same on record.

For and on behalf of **OneSource Specialty Pharma Limited**

Trisha A

Company Secretary and Compliance Officer

Membership Number: A47635